CA
AGIO icon

Centerpoint Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Centerpoint Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-473
Closed -$17K – 247
2020
Q3 		$17K Hold
473
– – 0.01% 125
2020
Q2 		$25K Hold
473
– – 0.02% 110
2020
Q1 		$17K Hold
473
– – 0.02% 122
2019
Q4 		$23K Hold
473
– – 0.02% 134
2019
Q3 		$15K Hold
473
– – 0.01% 140
2019
Q2 		$24K Buy
+473
New +$25.3K 0.02% 125

Other funds holding AGIO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Centerpoint Advisors's AGIO Position: Q4 2020 in Review

Centerpoint Advisors sold out of Agios Pharmaceuticals (AGIO) in Q4 2020, closing a stake of 473 shares — an estimated $17K sold.

Centerpoint Advisors first reported a position in AGIO in Q2 2019 and held it in 6 quarters. The position peaked at $25K in Q2 2020. 200 funds tracked by Wall St. Rank hold AGIO as of Q4 2020.

  • Centerpoint Advisors reported no remaining Agios Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Centerpoint Advisors sold 473 Agios Pharmaceuticals shares in Q4 2020, an estimated $17K.
  • Centerpoint Advisors first reported a position in Agios Pharmaceuticals in Q2 2019 and held it in 6 quarters.
  • Centerpoint Advisors's Agios Pharmaceuticals position peaked at $25K in Q2 2020.
  • 200 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2020.

Based on Centerpoint Advisors's 13F filing for Q4 2020, filed 22 Jan 2021.